TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20195744
Drug: Adjuvant! estimate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant! estimate for endocrine therapy alone
Study: 20195744
Drug: Adjuvant! estimate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant! estimate for chemoendocrine therapy
Study: 17919634
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT) with 6 sessions of supportive therapy.
Study: 11674922
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (sublingual immunotherapy with a biologically standardised extract of three pollens)
Study: 11674922
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (sublingual immunotherapy) during the second year
Study: 2882607
Drug: Propoxyphene napsylate
Normalized name: Propoxyphene Napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene napsylate with acetaminophen (PN/A, 100 mg with 650 mg)
Study: 31679865
Drug: MF59®‐adjuvanted trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59®‐adjuvanted trivalent influenza vaccine (aTIV; Fluad®)
Study: 31679865
Drug: Highest dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest dosage of antigen in combination with the highest dosage of adjuvant
Study: 31679865
Drug: Modified aTIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified aTIV formulations
Study: 26763271
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (1000 impulses and 2.1 bar)
Study: 24074486
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Clopidogrel dual therapy
Study: 24074486
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group (patients on anti-platelet therapy)
Study: 20649945
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied pure lavender oil (1 ml of 30% high strength essential lavender oil)
Study: 18207205
Drug: Astringent solution
Normalized name: Aluminum Acetate Astringent Solution Packets
DrugBank: Aluminum acetate (DB14518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Astringent solution (5 g L(‐1) tannic acid in distilled water)
Study: 18207205
Drug: Sweet solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweet solution (40 g L(‐1) sugar in mango tea with no tannins)
Study: 16415706
Drug: Reduced-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose group
Study: 16415706
Drug: Fixed-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose group
Study: 1632166
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.3 mg) + bupivacaine (20 mg)
Study: 1632166
Drug: Postoperative naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative naloxone infusion (1 microgram/kg/h over 12 h, 0.25 micrograms/kg/h over the next 12 h) + bupivacaine (20 mg) + morphine (0.3 mg)
Study: 1632166
Drug: Bupivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (20 mg)
Study: 26260354
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii 250 mg
Study: 26260354
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii 250 mg plus BS 524 mg
Study: 26260354
Drug: BS 524
Normalized name: BS-001
DrugBank: BS-001 (DB17415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BS 524 mg
Study: 19362455
Drug: Bitter melon
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter melon (55 ml/24h)
Study: 19362455
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/24h)
Study: 18500525
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of oral contrast agent
Study: 18500525
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml of oral contrast agent
Study: 18500525
Drug: 450 ml
Normalized name: ALCOHOL 270 mL in 450 mL EXTRACORPOREAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 ml of oral contrast agent
Study: 15509637
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE, 100 mg im weekly) + levonorgestrel (LNG, 125 microg orally daily)
Study: 15509637
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE, 100 mg im weekly) + levonorgestrel (LNG, 125 microg orally daily) + dutasteride (0.5 mg orally daily)
Study: 15509637
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE, 100 mg im weekly) + acyline (300 microg/kg sc every 2 wk)
Study: 15509637
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE, 100 mg im weekly) + levonorgestrel (LNG, 125 microg orally daily) + acyline (300 microg/kg sc every 2 wk)
Study: 12523585
Drug: O 20
Normalized name: ABO 201
DrugBank: ABO-201 (DB17951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O 20 mg, clarithromycin (C) 250 mg, metronidazole (M) 500 mg (O.C.M)
Study: 12523585
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg, clarithromycin (C) 250 mg, metronidazole (M) 500 mg (RBC.C.M)
Study: 12523585
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg, tetracycline (T) 1000 mg, metronidazole (M) 500 mg (RBC.T.M)
Study: 10375099
Drug: Chronomodulated 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronomodulated 5‐FU (700 mg/m2/day), LV (300 mg/m2/day), and 1‐OHP (25 mg/m2/day) for 4 days every 14 days.
Study: 1767242
Drug: Aniracetam (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aniracetam (1500 mg/day per os)
Study: 30665504
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of normal saline solution during 1 hour
Study: 30665504
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution at 10 mL/hour for 1 hour (control group)
Study: 25274266
Drug: LDRnHBT (Low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDRnHBT (Low-dose radon hyperthermia balneo treatment)
Study: 25274266
Drug: Combined hyperthermia
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hyperthermia balneo and exercise treatment
Study: 19324944
Drug: Chlorogenic acid
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorogenic acid (1 g)
Study: 19324944
Drug: Trigonelline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigonelline (500 mg)
Study: 19324944
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g mannitol)
Study: 11522582
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) 20 mg daily subcutaneous injections
Study: 3291074
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of diethylcarbamazine (DEC) - 30 mg/kg/d for one week preceded by a one week initial treatment with normal oral doses of DEC or DEC lotion
Study: 29420189
Drug: DOUBLE (double-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOUBLE (double-dose clopidogrel)
Study: 29420189
Drug: TRIPLE (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRIPLE (adjunctive cilostazol)
Study: 29420189
Drug: STANDARD (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: STANDARD (standard dual antiplatelet therapy)
Study: 24088688
Drug: Integration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration of family planning services into HIV care and treatment clinics
Study: 20505750
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of L-NMMA
Study: 12356000
Drug: Indapamid SR
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamid SR 1.5 mg
Study: 1918848
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (1 microgram/kg/min)
Study: 27091717
Drug: Low-dose corticosteroid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticosteroid prophylaxis (group B, n = 72)
Study: 27091717
Drug: Low-dose corticosteroid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticosteroid prophylaxis (group B)
Study: 21039933
Drug: Garlic extract
Normalized name: Garlic Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic extract supplementation at 250 mg/kg BW/day/calf
Study: 16775418
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m(2))
Study: 16775418
Drug: Docetaxel (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (15 mg/m(2)) with ketoconazole (400 mg 3 times daily)
Study: 11253342
Drug: External compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: External compression with early mobilization and Low Molecular Weight Heparin (LMWH) therapy
Study: 9189045
Drug: Gabapentin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (up to 900 mg/day)
Study: 9189045
Drug: Baclofen (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (up to 30 mg/day)
Study: 30457433
Drug: Glycopyrrolate/eFlow CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate/eFlow CS 50 μg twice daily
Study: 30457433
Drug: Tiotropium 18 μg
Normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg once daily (administered via HandiHaler™)
Study: 28544344
Drug: MPH XR-ODT
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH XR-ODT (60 mg) administered in a fed state
Study: 28544344
Drug: MPH XR-ODT
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH XR-ODT (60 mg) administered in a fasted state
Study: 28544344
Drug: MPH XR-ODT
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH XR-ODT (60 mg)
Study: 22353395
Drug: BAY 86-6150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 86-6150 (6.5, 20, 50 or 90 μg kg(‐1))
Study: 18853615
Drug: Mirazid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirazid (10 mg/kg for 2 weeks)
Study: 18853615
Drug: Paromomycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin (500 mg qid for 2 weeks)
Study: 18853615
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Mirazid (10 mg/kg) and Paromomycin (500 mg) for two weeks
Study: 12827065
Drug: Anticoagulants (general)
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (general)
Study: 10669150
Drug: Daily 2
Normalized name: CVS Oil-Free Daily 2% Acne Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 2 mg micronised oestradiol (E2)
Study: 10669150
Drug: Daily 2
Normalized name: CVS Oil-Free Daily 2% Acne Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 2 mg micronised oestradiol combined with a progestagen for 14 days of each cycle (E2+P)
Study: 10669150
Drug: Daily 2
Normalized name: CVS Oil-Free Daily 2% Acne Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 2 mg micronised oestradiol (E2) and E2+P
Study: 8797400
Drug: Albuterol and
Normalized name: Albuterol and cromolyn only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol and ipratropium (2.5 mg albuterol + 0.5 mg ipratropium)
Study: 8797400
Drug: Albuterol alone
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol alone (2.5 mg)
Study: 1468911
Drug: Tizanidine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (6 mg/day, increased to 18 mg/day based on response)
Study: 3979577
Drug: Low-dose danazol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose danazol (100 mg/24 hours)
Study: 31746880
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein treatments (both ratios)
Study: 16214825
Drug: High-risk group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk group defined by ITPA 94C > A or TPMT <10 nmol/(mL erythrocytes . h)
Study: 9783399
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent influenza split vaccine (IIV)
Study: 9783399
Drug: Live trivalent
Normalized name: influenza virus vaccine, live trivalent nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live trivalent influenza allantoic vaccine (LIV)
Study: 9783399
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent influenza split vaccine (IIV) alone
Study: 9783399
Drug: Live trivalent
Normalized name: influenza virus vaccine, live trivalent nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live trivalent influenza allantoic vaccine (LIV) alone
Study: 8072991
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (600 mg and 1200 mg daily)
Study: 8072991
Drug: Sugar-reducing drugs
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-reducing drugs and insulin
Study: 3383879
Drug: Molsidomine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (8 mg)
Study: 27403645
Drug: saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 5 mg/d
Study: 24606097
Drug: Cholecalciferol (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (40,000 IU weekly)
Study: 19825207
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g dark chocolate with 500 mg polyphenols
Study: 19825207
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g dark chocolate with 1000 mg polyphenols
Study: 19825207
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of dark chocolate
Study: 9689420
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release tablet (40 mg)
Study: 9689420
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (20 mg)
Study: 7857348
Drug: Pidotimod (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod (400 mg ampoule twice a day)
Study: 2776821
Drug: verapamil-SR 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil-SR 360 mg once daily
Study: 2776821
Drug: verapamil-IR 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil-IR 120 mg t.i.d.
Study: 2776821
Drug: verapamil-SR 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil-SR 240 mg
Study: 29143926
Drug: Moisturizer plus
Normalized name: ALCOHOL 0.7 L in 1 L TOPICAL GEL [Fusoni Hand Sanitizer with Moisturizer Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moisturizer plus body wash (twice daily moisturizer and once daily body wash)
Study: 29143926
Drug: Body wash
Normalized name: Olay Body Wash
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Body wash alone (once daily)
Study: 19371267
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg day(-1))
Study: 19371267
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg day(-1))
Study: 17029278
Drug: BTX type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX type A (BTX‐A) plus a specific program of physical therapy (BTX‐PT)
Study: 11394701
Drug: Heparin lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin lock
Study: 8098788
Drug: Gln TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gln TPN (parenteral nutrition enriched with glycyl‐L‐glutamine)
Study: 8098788
Drug: STPN (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: STPN (standard parenteral nutrition)
Study: 3548350
Drug: Suramin (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin (0.5, 1.0, or 1.5 g weekly for up to six months)
Study: 29480316
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g oat β-glucan (OBG)
Study: 29480316
Drug: 0.4 g
Normalized name: psyllium 0.4 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g oat β-glucan (OBG)
Study: 29480316
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g oat β-glucan (OBG)
Study: 29480316
Drug: Instant oatmeal
Normalized name: OATMEAL
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant oatmeal plus 247 g 2% milk (IO)
Study: 29480316
Drug: Cream of
Normalized name: Nubasics Soup Cream of Chicken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream of rice (CR) plus milk
Study: 27595528
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin/day for 2 days preoperatively
Study: 27595528
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of atorvastatin/day for 5‐9 days preoperatively
Study: 27595528
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin/day for 5‐9 days preoperatively
Study: 20519098
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg/d)
Study: 20519098
Drug: Prednisolone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (5 mg/d)
Study: 10597203
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biological risk factor analysis and CT staging
Study: 7489937
Drug: Aspirin 1200
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1200 mg daily
Study: 28544128
Drug: Cetuximab with
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab with radiation therapy followed by adjuvant cetuximab and irinotecan (5,940 cGy radiation, cetuximab weekly, irinotecan daily for 5 days per week for 2 weeks every 21 days for 30 weeks)
Study: 25869284
Drug: Continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing of pomalidomide/dexamethasone
Study: 25869284
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing of pomalidomide/dexamethasone
Study: 25869284
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing regimens (continuous and intermittent)
Study: 20025778
Drug: Oxytocin (intranasal)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (intranasal)
Study: 17488782
Drug: Slow-release oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release oral misoprostol (800 microg)
Study: 17488782
Drug: Conventional misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional misoprostol (vaginal or sublingual)
Study: 7944416
Drug: OK-432 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 administered preoperatively via hepatic artery
Study: 7959572
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with OK-432)
Study: 3284269
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg thiopentone
Study: 3284269
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg thiopentone
Study: 2177499
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline capsules (administered daily for 2 weeks)
Study: 2177499
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (administered daily for 2 weeks)
Study: 2177499
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline capsules (in vitro exposure)
Study: 2177499
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline capsules (in additional subjects)
Study: 27711048
Drug: RG7713 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7713 (20 mg intravenous dose)
Study: 15539964
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg monotherapy
Study: 15539964
Drug: ER niacin
Normalized name: Leader Niacin 500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER niacin 2 g monotherapy
Study: 15539964
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus ER niacin 2 g
Study: 15539964
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus ER niacin 0.5-2 g
Study: 15539964
Drug: Rosuvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin monotherapy